TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16005708
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy (DBT) for 52 weeks
Study: 10357919
Drug: Cell-free extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cell-free extracorporeal perfusion with hypertonic, hyperoncotic perfusate containing anti-oxidants (mean volume 1835 +/- 824 ml)
Study: 8520059
Drug: Podophyllotoxin cream
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin cream (0.5%)
Study: 1744356
Drug: Albuterol, Cromolyn,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol, Cromolyn, Combination of Albuterol and Cromolyn
Study: 6336645
Drug: Glucagon hydrochloride
Normalized name: Glucagon Hydrochloride
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon hydrochloride 1 mg intravenously
Study: 30560738
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) for 16 weeks
Study: 30560738
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (ADM) for 16 weeks
Study: 29466592
Drug: Diet-insulin secretion
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet-insulin secretion (INS-30) interaction
Study: 17688076
Drug: Ranitab 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitab 150 mg film tablets (test preparation)
Study: 17688076
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg film tablets of the originator product (reference preparation)
Study: 7653829
Drug: Etomidate (0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.15, 0.2, and 0.3 mg/kg)
Study: 7653829
Drug: Methohexital (0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (0.75, 1.0, and 1.5 mg/kg)
Study: 7653829
Drug: Propofol (0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.75, 1.0, and 1.5 mg/kg)
Study: 2476426
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of twice daily fractionation (370 cGy/fraction totaling 1480 cGy/course) for three courses (total dose 4440 cGy)
Study: 2476426
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of twice daily fractionation (370 cGy/fraction totaling 1480 cGy/course)
Study: 1203889
Drug: cis-dichlorodiammineplatinum(II) in
Normalized name: CIS-DIAMMINEDICHLOROPLATINUM II
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cis-dichlorodiammineplatinum(II) in combination with four other chemotherapeutic agents
Study: 26417092
Drug: Opioid antagonist
Normalized name: OPIOID ANTAGONIST ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid antagonist (naltrexone)
Study: 23690338
Drug: DRSP/EE-metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRSP/EE-metformin
Study: 27871268
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg oral tablets, increasing to a maximum of 1000 mg twice daily)
Study: 27871268
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical appearing and tasting tablets)
Study: 25372087
Drug: Screening with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening with low-dose CT
Study: 21338205
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of risk factors for oral cancer (tobacco and alcohol)
Study: 21338205
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of signs of oral cancer (white and red lesions)
Study: 6831836
Drug: L‐adrenaline 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐adrenaline 0.025 micrograms min‐1 kg‐1
Study: 6831836
Drug: L‐adrenaline 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐adrenaline 0.05 micrograms min‐1 kg‐1
Study: 25550337
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg abatacept
Study: 21279703
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose gemcitabine (100 mg/m² over 30 min 1-2 h before radiotherapy)
Study: 21279703
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose paclitaxel (20 mg/m² over 60 min 4-6 h before radiotherapy)
Study: 21279703
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose gemcitabine
Study: 21279703
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose paclitaxel
Study: 19453519
Drug: Autologous chondrocyte
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous chondrocyte implantation and combination products; specific dosage and duration not mentioned.
Study: 17549880
Drug: Training for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training for fathers, details on dosage and duration not available
Study: 10101624
Drug: Caudal anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal anaesthesia with bupivacaine 0.25% 1 mL kg‐1 combined with general anaesthesia but without opioids
Study: 10101624
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia including intravenous fentanyl
Study: 8789469
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (group HC)
Study: 27836979
Drug: Mild ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild ovarian stimulation strategy (low-dose gonadotropins 150 IU FSH, GnRH-antagonist)
Study: 27836979
Drug: Conventional ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ovarian stimulation strategy (high-dose gonadotropins 450 IU HMG, long mid-luteal GnRH-agonist)
Study: 9555597
Drug: ondansetron 2
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 2 mg twice daily
Study: 7990068
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control procedure
Study: 28168769
Drug: 0.1% TAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% TAC ointment (n = 11)
Study: 21266004
Drug: Local and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local and intraarticular analgesic injection (LIA) composed of 5 mg morphine, 30 mg bupivacaine (15 mg/1.5 mL), 1 mL betamethasone, and 0.5 mL epinephrine (1:1,000)
Study: 21266004
Drug: Local and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local and intraarticular analgesic injection (LIA)
Study: 19432231
Drug: Vitaprost tablets
Normalized name: limaprost
DrugBank: Limaprost (DB09211)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vitaprost tablets
Study: 9236504
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with nasal saline, sulfamethoxazole‐trimethoprim, antihistamine/decongestant, and five days of prednisone.
Study: 9236504
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-treatment control).
Study: 28931460
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of computerized EF training (1h sessions 3 times per week and 40min daily home training)
Study: 26953193
Drug: Isavuconazole (prodrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (prodrug isavuconazonium sulfate); administered intravenously and orally; specific dosage and duration not mentioned
Study: 24331121
Drug: L-PRF (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF (N = 10)
Study: 8110548
Drug: Sufentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil at a plasma concentration of 0.145 ng ml‐1
Study: 8110548
Drug: Sufentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil at a plasma concentration greater than 0.5 ng ml‐1
Study: 8110548
Drug: Plasma fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma fentanyl concentration of 1.67 ng ml‐1
Study: 30900980
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol 0.02 mg + levonorgestrel 0.10 mg + folic acid 0.4 mg
Study: 30900980
Drug: placebo coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo coated tablet containing folic acid 0.4 mg only
Study: 19567496
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (< 4 h of use)
Study: 15108041
Drug: Chemotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy group (MMC + 5‐FU + HCFU)
Study: 15108041
Drug: Chemotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy group (MMC + 5‐FU + UFT)
Study: 11018229
Drug: Family-focused psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused psychoeducational treatment (FFT) - 21 sessions over 9 months
Study: 11018229
Drug: Comparison treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison treatment (CM) - 2 family education sessions and follow-up crisis management over 9 months
Study: 8364194
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg body weight i.v. IgG infusion
Study: 8364194
Drug: 2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg body weight i.v. IgG infusion
Study: 8364194
Drug: six 1
Normalized name: Lasix 1 MG/ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: six 1 g/kg body weight i.v. IgG reinfusions
Study: 26165216
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTX) injections
Study: 26165216
Drug: Saline (NaCl)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (NaCl) injections
Study: 21807618
Drug: Atorvastatin intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin intervention (10 mg for 3 months)
Study: 21807618
Drug: Localized BH(4)
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized BH(4) after atorvastatin
Study: 21807618
Drug: Combo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combo after atorvastatin
Study: 19896021
Drug: Low-literacy medication
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-literacy medication education tool
Study: 9296514
Drug: Vaccinia melanoma
Normalized name: vaccinia virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinia melanoma oncolysate (VMO) vaccine
Study: 9296514
Drug: Placebo vaccinia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaccinia vaccine virus (V)
Study: 8370370
Drug: Nicorandil, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil, 20 mg b.d.
Study: 8370370
Drug: Diltiazem, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 60 mg t.d.
Study: 22267751
Drug: Irbesartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (up to 300 mg daily)
Study: 1686746
Drug: dilevalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: dilevalol (200 mg, 400 mg or 600 mg)
Study: 17616473
Drug: Intravenous valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous valproate (IV VA)
Study: 17616473
Drug: Intravenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phenytoin (IV phenytoin)
Study: 12418118
Drug: Propranolol 40-80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40-80 mg
Study: 12418118
Drug: Trimetazidine 20
Normalized name: trimetazidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 20 mg
Study: 12418118
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propranolol 40 mg and Trimetazidine 20 mg
Study: 12418118
Drug: Trimetazidine 60
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 60 mg/day
Study: 12418118
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propranolol 120 mg/day and Trimetazidine 60 mg/day
Study: 10613408
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester (3 grams daily from three servings of spread containing one gram of plant stanols each)
Study: 8564625
Drug: Bitolterol mesylate
Normalized name: Bitolterol Mesylate
DrugBank: Bitolterol (DB00901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bitolterol mesylate metered-dose inhaler (1, 2, or 3 inhalations)
Study: 6749458
Drug: Intravenous branched-chain
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous branched-chain amino acid solutions in 20% glucose (group A)
Study: 31669427
Drug: Routine blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine blood parameters (platelet count, CRP levels, GMI) during antifungal treatment
Study: 25725903
Drug: 8-week exercise
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week exercise program with elastic bands, twice a week
Study: 24297587
Drug: Early post-surgical
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early post-surgical radiation therapy (within 3 months)
Study: 24297587
Drug: Late post-surgical
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late post-surgical radiation therapy (at disease progression)
Study: 21098003
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (Bicarb, 1 M; 350‐500 ml)
Study: 17317757
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anaesthesia (TIVA)
Study: 8239161
Drug: Budesonide tapering-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide tapering-off (decrease dose within 2 months, followed by placebo for 4 months)
Study: 3159162
Drug: Miconazole 2%
Normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole 2% + benzoyl peroxide 5% (Acnidazil) applied twice a day
Study: 30352035
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (IAYT training for 14 weeks, 1.5 hours daily for 5 days a week)
Study: 24867391
Drug: Perampanel (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (12 mg/day or individual maximum tolerated dose)
Study: 20373477
Drug: Clozapine, Olanzapine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine, Olanzapine, Haloperidol, Risperidone (antipsychotics)
Study: 1282465
Drug: CCK8 (graded
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK8 (graded doses)
Study: 30466808
Drug: Psychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications (antidepressants and anxiolytics)
Study: 30466808
Drug: Antidepressants (pre-existing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (pre-existing prescriptions)
Study: 30466808
Drug: Antidepressants (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (new prescriptions perioperatively)
Study: 26481873
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention (remote monitoring/management of chemotherapy side-effects) in addition to 'Usual Care'.
Study: 21248294
Drug: Individuals with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals with insulin resistance (IR)
Study: 12691336
Drug: Exercise twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise twice a week
Study: 2287558
Drug: Caffeine 65
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 65 mg
Study: 2287558
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg + Caffeine 65 mg
Study: 25701373
Drug: De novo
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De novo low-dose tacrolimus/sirolimus (lowTAC/SIR)
Study: 25701373
Drug: Full-dose tacrolimus/mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose tacrolimus/mycophenolate mofetil (TAC/MMF)
Study: 18636790
Drug: Efalizumab 1
Normalized name: efalizumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 1 mg/kg/wk for 48 weeks
Study: 12610022
Drug: Losartan and
Normalized name: losartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan and conventional antihypertensive therapy (CT)
Study: 12610022
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and conventional antihypertensive therapy (CT)
Study: 7034642
Drug: Amoxicillin only
Normalized name: Amoxicillin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin only
Study: 18823361
Drug: Combination without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination without caffeine
Study: 18823361
Drug: Single preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preparations
Study: 17826421
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of antenatal corticosteroids (R-ACS)
Study: 14713401
Drug: Glucosamine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine therapy
Study: 10968496
Drug: 3,200 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,200 microg budesonide daily for 8 weeks
Study: 10968496
Drug: 1,600 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,600 microg budesonide daily for 8 weeks
Study: 9280188
Drug: DHA (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (3.6 g/d)
Study: 9280188
Drug: EPA (3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (3.8 g/d)
Study: 9280188
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (4.0 g/d, placebo)
Study: 8315953
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) 5 mg/kg/day for adults, 6 mg/kg/day for children for six months, then tapered off by 25% every two months until complete discontinuation.
Study: 30514992
Drug: Motion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion therapy procedure
Study: 30514992
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no motion therapy)
Study: 27429618
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy in addition to conventional periodontal therapy
Study: 12784108
Drug: Estrogen (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (transdermal administration over 3 days)
Study: 12784108
Drug: Testosterone (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (transdermal administration over 3 days)
Study: 10647762
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (tinzaparin sodium) given once daily
Study: 10647762
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (dose-adjusted)
Study: 1391257
Drug: Freshly frozen
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freshly frozen plasma infusion (FFP) 10 ml/kg on days 1-3
Study: 31027191
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of vitamin D and aerobic training (DAT)
Study: 24079645
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mitiglinide and voglibose (1 tablet 3 times daily)
Study: 16824852
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE 0.625 mg/d)
Study: 11290865
Drug: R115777 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: R115777 200 mg/dose, escalated to 300 mg b.i.d. for 28 days
Study: 11290865
Drug: R115777 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: R115777 300 mg b.i.d. for 28 days
Study: 11290865
Drug: R115777 pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: R115777 pharmacokinetics
Study: 3066417
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral tablet of lorazepam
Study: 3066417
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg sublingual tablet of lorazepam
Study: 2250886
Drug: Lid scrubs
Normalized name: Scrub-Stat
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lid scrubs and massage for MGD treatment
Study: 2250886
Drug: Subjective comfort
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective comfort with contact lens wear after therapy
Study: 27815511
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg once daily (QD)
Study: 30574343
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg twice daily (BID)